PMID- 35133014
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 36
IP  - 3
DP  - 2022 Mar
TI  - Associations of serum amyloid A and 25-hydroxyvitamin D with diabetic 
      nephropathy: A cross-sectional study.
PG  - e24283
LID - 10.1002/jcla.24283 [doi]
LID - e24283
AB  - BACKGROUND: The present study investigated the relationships between serum 
      amyloid A (SAA), 25-hydroxyvitamin D (25(OH)VD) and diabetic nephropathy (DN) to 
      provide evidence for the prevention and management of DN. METHODS: A total of 182 
      patients with type 2 diabetes mellitus (T2DM) were enrolled in this study. The 
      levels of SAA, 25(OH)VD, and other conventional indicators were measured and 
      analyzed. Receiver operating characteristic curve analysis was applied for the 
      combined measurement of SAA and 25(OH)VD, and risk factors for DN were evaluated 
      using binary logistic regression analysis. RESULTS: The levels of SAA in T2DM 
      patients were significantly higher than those in healthy subjects, and the level 
      significantly increased with the progression of DN (p < 0.05). In contrast, the 
      level of 25(OH)VD in T2DM patients was significantly lower than that in healthy 
      subjects, and the level significantly decreased with the progression of DN 
      (p < 0.05). The combined measurement of SAA and 25(OH)VD distinguished DN 
      patients from T2DM patients better than the measurement of SAA or 25(OH)VD alone. 
      SAA was an independent risk factor for DN, and 25(OH)VD was an independent 
      protective factor for DN. CONCLUSION: SAA and 25(OH)VD might be used as potential 
      markers to identify patients at increased risk of developing DN.
CI  - (c) 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals LLC.
FAU - Liu, Qian
AU  - Liu Q
AD  - Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, 
      Lianyungang, China.
FAU - Sun, Jin
AU  - Sun J
AD  - Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, 
      Lianyungang, China.
FAU - Xu, Tongdao
AU  - Xu T
AD  - Department of Endocrinology, The Second People's Hospital of Lianyungang, 
      Lianyungang, China.
FAU - Bian, Guangrong
AU  - Bian G
AD  - Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, 
      Lianyungang, China.
FAU - Yang, Fumeng
AU  - Yang F
AUID- ORCID: 0000-0002-2636-7340
AD  - Department of Laboratory Medicine, The Second People's Hospital of Lianyungang, 
      Lianyungang, China.
LA  - eng
GR  - TQ202101/Young and Middle-aged Medical Talent Growth Fund of the Second People's 
      Hospital of Lianyungang/
GR  - 2020byzd342/Key Project of the Natural Science Foundation of Bengbu Medical 
      College/
PT  - Journal Article
DEP - 20220208
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Serum Amyloid A Protein)
RN  - 1406-16-2 (Vitamin D)
RN  - A288AR3C9H (25-hydroxyvitamin D)
SB  - IM
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Diabetic Nephropathies
MH  - Humans
MH  - Serum Amyloid A Protein
MH  - Vitamin D/analogs & derivatives
PMC - PMC8906018
OTO - NOTNLM
OT  - 25-hydroxyvitamin D
OT  - diabetic nephropathy
OT  - serum amyloid A
OT  - type 2 diabetes mellitus
COIS- The authors declare no potential conflicts of interest with respect to the study, 
      authorship, and/or publication of this article.
EDAT- 2022/02/09 06:00
MHDA- 2022/04/08 06:00
PMCR- 2022/02/08
CRDT- 2022/02/08 08:40
PHST- 2022/01/25 00:00 [revised]
PHST- 2021/12/30 00:00 [received]
PHST- 2022/01/28 00:00 [accepted]
PHST- 2022/02/09 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2022/02/08 08:40 [entrez]
PHST- 2022/02/08 00:00 [pmc-release]
AID - JCLA24283 [pii]
AID - 10.1002/jcla.24283 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2022 Mar;36(3):e24283. doi: 10.1002/jcla.24283. Epub 2022 Feb 8.